Association between pan-immune-inflammation value and heart failure: Evidence from the NHANES 2011–2020
Journal of International Medical Research,
Journal Year:
2025,
Volume and Issue:
53(3)
Published: March 1, 2025
Objective
This
study
aimed
to
explore
the
association
between
pan-immune-inflammation
value
and
heart
failure
outcomes
using
data
from
nationally
representative
National
Health
Nutrition
Examination
Survey
database.
Methods
We
conduct
a
cross-sectional
cohort
analysis
data,
including
participants
aged
≥20
years
with
available
data.
performed
smooth
curve
fitting
threshold
analysis,
both
linear
non-linear
regression
models,
assess
dose–response
relationship
continuous
effect
of
on
outcomes.
Results
Our
revealed
significant
independent
elevated
levels
an
increased
risk
occurrence.
After
adjustment
for
multiple
covariates,
these
findings
remained
consistent
each
increment
unit
in
logarithmic
is
associated
34%
increase
Furthermore,
we
identified
inflection
point
=
5.98
as
critical
threshold.
Stratified
analyses
that
occurrence
remains
across
different
subgroups.
Conclusions
confirmed
clinical
novel
inflammatory
biomarker
assessment
monitoring
failure.
Language: Английский
Oral selective estrogen receptor degraders (SERDs) in Hormone receptor-Positive HER2-Negative Metastatic breast cancer After Progression with CDK4/6 inhibitors
Expert Review of Anticancer Therapy,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 13, 2025
Hormone
receptor-positive
(HR+),
HER2-negative
metastatic
breast
cancer
(mBC)
remains
a
prevalent
and
challenging
disease.
Endocrine
therapy
(ET)
combined
with
CDK4/6
inhibitors
is
the
first-line
standard
of
care,
yet
resistance
mechanisms,
including
ESR1
mutations,
drive
disease
progression.
Novel
oral
selective
estrogen
receptor
degraders
(SERDs)
have
emerged
as
promising
therapeutic
agents
after
progression
secondary
to
mutations.
However,
available
studies
on
SERDs
differ
in
design,
study
population,
outcomes,
necessitating
critical
review
data.
This
explores
clinical
efficacy,
safety
profiles
HR-positive,
mBC,
particularly
following
inhibitors.
Recent
key
trials,
EMERALD,
SERENA-2,
EMBER-3
AMEERA-3,
are
analyzed,
highlighting
their
efficacy
overcoming
resistance,
especially
ESR1-mutant
populations.
Oral
offer
enhanced
bioavailability
convenience
compared
fulvestrant,
representing
advancement
endocrine
therapy.
Their
integration
into
treatment
strategies,
combination
regimens
ctDNA-driven
approaches,
may
improve
patient
outcomes
address
mechanisms.
other
than
refinement
for
selection
limited.
Further
trials
needed
optimize
SERD
use
define
most
effective
strategies
SERDs.
Language: Английский
EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(22), P. 12191 - 12191
Published: Nov. 13, 2024
Erythropoietin-producing
hepatocellular
A2
(EphA2)
is
a
member
of
the
Eph
tyrosine
kinase
receptor
family
that
has
been
linked
to
various
biological
processes.
In
tumors,
EphA2
overexpression
associated
with
noncanonical
pathway
activation,
tumor
progression,
and
poor
prognosis,
which
emphasized
its
importance
as
marker
malignancy.
Studies
on
numerous
cancer
models
have
highlighted
EphA2’s
dual
often
contradictory
action,
can
be
attributed
EphA2′s
interactions
involving
multiple
pathways
different
ligands,
well
heterogeneity
microenvironment.
this
review,
we
summarize
main
mechanisms
underlying
dysregulation
in
cancer,
highlighting
molecular
complexity.
Then,
analyze
therapies
developed
over
time
counteract
action.
We
discuss
limitations
described
approaches,
emphasizing
fact
goal
new
options
high
specificity
without
losing
therapeutic
efficacy.
For
reason,
immunotherapy
or
emerging
field
targeted
protein
degradation
proteolysis-targeting
chimeras
(PROTACs)
may
represent
promising
solution
based
deeper
understanding
sustaining
oncogenic
activity.
Language: Английский